A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia

Trial Profile

A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Durvalumab (Primary) ; Bendamustine; Ibrutinib; Lenalidomide; Rituximab
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FUSION NHL 001
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 27 Jul 2017 According to a celgene corporation media release, data from this trial is expected in second half of 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top